A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

  • End date
    Aug 1, 2024
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 1 October 2021


This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.

Condition Liver Metastases, Brain Metastases, metastasized, Bone Metastases, Cancer, Metastatic, metastases, secondaries, Neoplasm Metastasis, cancers metastatic, secondary cancer, Metastasis, Metastatic Cancer, metastatic disease, metastatic tumor
Treatment Palliative radiotherapy
Clinical Study IdentifierNCT05010031
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on1 October 2021


Yes No Not Sure

Inclusion Criteria

Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy
Pathogenic mutation in ATM (somatic and germline allowed)
ECOG performance status 0-2
Age 18 years
Able to provide informed consent
Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments
Expected life expectancy of at least 6 months

Exclusion Criteria

Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances
Serious medical co-morbidities precluding radiotherapy
Pregnant or breast-feeding women
Concomitant pathogenic mutation in p53
Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note